Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups

Michele Simbolo, Matteo Fassan, Andrea Ruzzenente, Andrea Mafficini, Laura D. Wood, Vincenzo Corbo, Davide Melisi, Giuseppe Malleo, Caterina Vicentini, Giorgio Malpeli, Davide Antonello, Nicola Sperandio, Paola Capelli, Anna Tomezzoli, Calogero Iacono, Rita T. Lawlor, Claudio Bassi, Ralph H. Hruban, Alfredo Guglielmi, Giampaolo TortoraFilippo de Braud, Aldo Scarpa

Research output: Contribution to journalArticlepeer-review


One-hundred-fifty-three biliary cancers, including 70 intrahepatic cholangiocarcinomas (ICC), 57 extrahepatic cholangiocarcinomas (ECC) and 26 gallbladder carcinomas (GBC) were assessed for mutations in 56 genes using multigene next-generation sequencing. Expression of EGFR and mTOR pathway genes was investigated by immunohistochemistry. At least one mutated gene was observed in 118/153 (77%) cancers. The genes most frequently involved were KRAS (28%), TP53 (18%), ARID1A (12%), IDH1/2 (9%), PBRM1 (9%), BAP1 (7%), and PIK3CA (7%). IDH1/2 (p=0.0005) and BAP1 (p=0.0097) mutations were characteristic of ICC, while KRAS (p=0.0019) and TP53 (p=0.0019) were more frequent in ECC and GBC. Multivariate analysis identified tumour stage and TP53 mutations as independent predictors of survival. Alterations in chromatin remodeling genes (ARID1A, BAP1, PBRM1, SMARCB1) were seen in 31% of cases. Potentially actionable mutations were seen in 104/153 (68%) cancers: i) KRAS/NRAS/BRAF mutations were found in 34% of cancers; ii) mTOR pathway activation was documented by immunohistochemistry in 51% of cases and by mutations in mTOR pathway genes in 19% of cancers; iii) TGF-ß/Smad signaling was altered in 10.5% cancers; iv) mutations in tyrosine kinase receptors were found in 9% cases. Our study identified molecular subgroups of cholangiocarcinomas that can be explored for specific drug targeting in clinical trials.

Original languageEnglish
Pages (from-to)2839-2852
Number of pages14
Issue number9
Publication statusPublished - 2014


  • Cholangiocarcinoma
  • Molecular subclassification
  • Multigene mutational panels
  • Next-generation sequencing
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)


Dive into the research topics of 'Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups'. Together they form a unique fingerprint.

Cite this